Media Pack
News

Current Edition

JCS Volume 15 Issue 4
 
Regional News

GlaxoSmithKline’s HIV drug Cabenuva scores FDA nod for 2-month dosing

Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it rem...
2 February 2022 Regional News approval | dosing
Continue Reading →
Regional News

GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare's HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around...
1 December 2021 Regional News Cabenuva | drug sales
Continue Reading →
Regional News

GlaxoSmithKline relocates US operations in Philadelphia, North Carolina as COVID-19 cuts its office space needs

Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in the U....
6 October 2021 Regional News biopharma | Excision BioTherapeutics
Continue Reading →
Regional News

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer...
29 September 2021 Regional News cabotegravir | FDA
Continue Reading →
Uncategorized

ViiV trials long-acting, two-drug HIV regimen

ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults w...
29 November 2017 Uncategorized antiviral | HIV
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte